A device that delivers low electrical impulses through a person’s skin. Used to treat some symptoms (such as neuropathyDamage or dysfunction of one or more nerves that typically results in numbness, tingling, muscle weakness and pain in the affected area. pain or bladder retention) of myelinAn insulating layer, or sheath that forms around nerves, including those in the brain and spinal cord. It is made up of protein and fatty substances. This myelin sheath allows electrical impulses to transmit quickly and efficiently along the nerve cells. If myelin is damaged, these impulses slow down. oligodendrocyte glycoproten antibodyA protective protein produced by your immune system that attaches to antigens (foreign substances), such as bacteria and toxins, and removes them from your body. In myelin oligodendrocyte glycoproten antibody disease (MOGAD), the body incorrectly produces an antibody that targets myelin oligodendrocyte glycoprotein, a component of the myelin sheath in the central nervous system. disease (MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease ).
Transcutaneous Electrical Nerve Stimulation (TENS Device)
Related Posts
Gabriela’s Story: A Story of Faith, Strength, and Resilience
My name is Gabriela Nunez, though most people know me as Gabby. I am 26 years old, a wife, and a proud mother of three
Eight Years Old and Running for Her Brother
When Aria laced up her trainers for the AJ Bell Great Manchester Run, she wasn’t just racing — she was advocating for her twin brother
Global Leaders in MOGAD Research Convened May 14-16, 2026
Leading international clinicians, researchers, advocates, and industry collaborators gathered in Cambridge, Massachusetts, for two major back-to-back MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease meetings focused onInflammation of the optic nerve that may be classified as unilateral (affecting one eye) or bilateral (affecting both eyes) that may result in vision changes, vision loss, and/or pain with eye movement. research priorities, clinical trials, therapeutic
